Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

benzinga.com/news/health-care/25/10/48283144/novartis-cancer-drug-shows-sustained-benefit-trial

On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).
The data demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months).
Results showed…

This story appeared on benzinga.com, 2025-10-17 18:02:58.
The Entire Business World on a Single Page. Free to Use →